See more : dormakaba Holding AG (DOKA.SW) Income Statement Analysis – Financial Results
Complete financial analysis of PPD, Inc. (PPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PPD, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- NetCents Technology Inc. (NC.CN) Income Statement Analysis – Financial Results
- Nemetschek SE (NEMA.SW) Income Statement Analysis – Financial Results
- Essar Securities Limited (ESSARSEC.BO) Income Statement Analysis – Financial Results
- B-RIGHT REALESTATE LIMITED (BRRL.BO) Income Statement Analysis – Financial Results
- Digimarc Corporation (DMRC) Income Statement Analysis – Financial Results
PPD, Inc. (PPD)
About PPD, Inc.
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 4.68B | 4.03B | 3.75B | 3.00B | 2.68B |
| Cost of Revenue | 2.88B | 2.41B | 2.27B | 1.54B | 1.39B |
| Gross Profit | 1.80B | 1.62B | 1.47B | 1.46B | 1.29B |
| Gross Profit Ratio | 38.42% | 40.24% | 39.32% | 48.80% | 48.25% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
| Operating Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
| Cost & Expenses | 4.17B | 3.61B | 3.35B | 2.74B | 2.37B |
| Interest Income | 0.00 | 0.00 | 5.45M | 3.55M | 2.51M |
| Interest Expense | 216.93M | 311.74M | 263.62M | 253.89M | 203.29M |
| Depreciation & Amortization | 279.12M | 264.83M | 258.97M | 279.07M | 260.49M |
| EBITDA | 668.54M | 627.35M | 666.36M | 544.62M | 630.92M |
| EBITDA Ratio | 14.28% | 15.56% | 17.77% | 18.15% | 23.55% |
| Operating Income | 509.43M | 418.49M | 402.24M | 261.33M | 314.26M |
| Operating Income Ratio | 10.88% | 10.38% | 10.73% | 8.71% | 11.73% |
| Total Other Income/Expenses | -321.88M | -359.21M | -255.61M | -244.86M | -147.37M |
| Income Before Tax | 187.55M | 59.28M | 146.63M | 16.47M | 166.89M |
| Income Before Tax Ratio | 4.01% | 1.47% | 3.91% | 0.55% | 6.23% |
| Income Tax Expense | 18.81M | 2.96M | 39.58M | -284.36M | -15.96M |
| Net Income | 153.69M | 47.82M | 104.19M | 296.03M | 183.10M |
| Net Income Ratio | 3.28% | 1.19% | 2.78% | 9.86% | 6.83% |
| EPS | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
| EPS Diluted | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
| Weighted Avg Shares Out | 346.68M | 339.43M | 324.30M | 325.04M | 324.22M |
| Weighted Avg Shares Out (Dil) | 346.68M | 339.43M | 324.30M | 325.86M | 324.30M |
PPD Reports First Quarter 2021 Results
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the first quarter ended March 31, 2021. Highlights Net authorizations growth of 39.3% over first quarter 2020 to $1,481.6 million, resulting in...
PPD Reports First Quarter 2021 Results
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Reports First Quarter 2021 Results
PPD and Science 37® Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development
WILMINGTON, N.C. & LOS ANGELES--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), and Science 37, developer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced an innovative collaboration in which PPD will be fully...
PPD and Science 37® Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development
WILMINGTON, N.C. & LOS ANGELES--(BUSINESS WIRE)--PPD and Science 37 Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development
PPD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PPD, Inc. - PPD
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of PPD, Inc. (NasdaqGS: PPD) to Thermo Fisher Scientific Inc. (NYSE: TMO)....
PPD Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of PPD, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PPD
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PPD, Inc. (NASDAQ: PPD) to Thermo Fisher Scientific Inc. for $47.50 per share is fair to PPD shareholders. Halper Sadeh encourages PPD shareholders...
PPD Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of PPD, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PPD
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PPD, Inc. (NASDAQ: PPD) to Thermo Fisher Scientific Inc. for $47.50 per share is fair to PPD shareholders. Halper Sadeh encourages PPD shareholders...
PPD, Inc. (PPD) Soars 6.5%: Is Further Upside Left in the Stock?
PPD, Inc. (PPD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
SHAREHOLDER ALERT: WeissLaw LLP Investigates PPD, Inc.
NEW YORK, April 15, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PPD, Inc. ("PPD" or the "Company") (NASDAQ: PPD) in connection with the proposed acquisition of...
Midday Market Update: The 10 Most Active Stocks Today
It's time for the midday market update for Thursday as several companies are on the move with various increases and decreases. The post Midday Market Update: The 10 Most Active Stocks Today appeared first on InvestorPlace.
Source: https://incomestatements.info
Category: Stock Reports